xCures wins second U.S. patent for structuring medical records in transit

xCures said the U.S. Patent and Trademark Office has granted its second U.S. patent, covering technology that converts unstructured medical records into decision-ready documents before they reach clinicians. The company says the method is already running across national health information networks and is central to its record-extraction platform.

Why it matters: - The patent protects a method designed to turn unreadable medical record bundles into structured data before clinicians or staff have to sort them by hand. - xCures says the approach reduces manual work, speeds decision-making, and lowers errors and costs when record requests return mixed faxes, PDFs, scans, and duplicates. - The method sits at the center of xCures Clinical Clarity Engine, which feeds the company’s Decision-Ready Checklists product.

What happened: - xCures announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,783,788, titled "Dynamic In-Transit Structuring of Unstructured Medical Documents." - The patent is xCures’ second issued U.S. patent. - The company said the patent covers the method used by the xCures Clinical Clarity Engine. - The patent issued on November 4, 2026.

The details: - The patented method parses record bundles into sub-documents and classifies items such as pathology, imaging, genomics, labs, clinic and progress notes, and diagnostic and prognostic reports. - Disease-specific ontologies drive metadata extraction. - A manifest acts as a table of contents for the full package. - The structured result is delivered in whatever format the recipient system accepts. - The company said the process links each element back to its source document so reviewers can verify the original record. - xCures said the method runs across Carequality, eHealth Exchange, and TEFCA through Kno2 as a Qualified Health Information Network. - The engine processes more than 1.5 million documents a day from more than 550,000 care locations across all 50 states. - The structured output feeds xCures Decision-Ready Checklists. - A peer-reviewed study published this year in AI in Precision Oncology reported checklist accuracy of 97.0% to 98.2%. - The patent names Mark A. Shapiro, Bryan J. Federowicz, and Glenn A. Kramer as inventors. - Wilson Sonsini Goodrich & Rosati prosecuted the application. - The patent issued with 50 claims and a patent term adjustment of 807 days. - xCures has filed a continuation application extending the family to system and computer-readable-medium claims. - Additional applications remain pending in the United States and China. - The company’s first issued U.S. patent, No. 11,887,738, "Platforms for Conducting Virtual Trials," was granted in January 2024. - The xCures Engine is HITRUST i1 certified. - xCures says its customers span diagnostics, telehealth and digital health, health systems, value-based care, and specialty pharmacy. - Customers include Caris, Veracyte, NeoGenomics, and Exact Sciences.

Between the lines: - The patent strengthens xCures’ position around the core workflow that turns raw records into usable clinical data. - The filing also signals that the company sees in-transit structuring as more than a feature; it is the architectural layer on top of which the rest of the platform runs. - The emphasis on source-document traceability suggests xCures is pitching both automation and auditability to healthcare buyers.

What’s next: - xCures said the patent family is still expanding through a continuation application and additional filings in the U.S. and China. - The company will keep scaling the engine across clinical domains and care workflows as more records arrive through national networks. - xCures says customers will continue to receive structured outputs through its web interface or API, with answers tied back to the source document.

The bottom line: - xCures now has patent protection around the step that converts chaotic incoming medical records into structured, decision-ready data before humans have to clean them up.